Fast BMI Assessment and Wegovy Delivery Process
Why BMI for Wegovy Matters - Next Day Delivery Available
The BMI requirement for Wegovy reflects the medication's licensing as a prescription-only medicine for specific weight management criteria. Adults with a BMI of 30 or above, or BMI 27-29.9 with weight-related comorbidities like type 2 diabetes or high blood pressure, may be eligible for treatment. Understanding your BMI for Wegovy eligibility is the first step, and once approved, our next day delivery service ensures you can begin treatment without delay.
EverydayMeds recognises that patients meeting the BMI for Wegovy criteria often want to start their weight management journey promptly. Our temperature-controlled delivery system maintains the medication's integrity during transport, crucial for this prescription-only medicine. The FlexTouch pen injection system requires proper cold-chain handling, which our next day delivery service provides as standard through our GPhC registered pharmacy operations.
Wegovy Pricing for All BMI-Eligible Patients
Once your BMI for Wegovy eligibility is confirmed, treatment costs are transparent and competitive. Single pens start at £79.99 for the initial 0.25mg dose, progressing to £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the maintenance 2.4mg dose. Our Getting Started bundles provide convenient multi-pen packages, such as the Intro Duo containing both 0.25mg and 0.5mg pens for £169.99.
Patients can apply discount codes at checkout to reach these final prices - new customers use FIRST40 while returning customers apply DOSE25. Bundle options like our Ultimate Stability Trio provide three months of maintenance supply for £649.99, offering convenience and Stock Available availability. All prices include next day delivery once your prescription is approved, with no hidden fees for our temperature-controlled packaging service.
Clinical Evidence for BMI-Based Wegovy Prescribing
The BMI criteria for Wegovy are based on extensive clinical trial evidence, particularly the STEP programme. In the landmark STEP 1 trial published by Wilding et al. in the New England Journal of Medicine (2021), patients taking Wegovy alongside a reduced-calorie diet and increased physical activity achieved approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo. These results established the medication's efficacy in the BMI ranges now licensed for treatment.
STEP 5 demonstrated sustained weight management, with patients maintaining approximately clinically studied weight loss at two years. The SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events, highlighting benefits beyond weight management for eligible BMI ranges. These evidence-based outcomes support the current NICE TA875 recommendation for Wegovy with specialist weight management support.
How Wegovy Works for Eligible BMI Patients
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural fullness hormone produced in the intestines. This mechanism works by reducing appetite and promoting feelings of satiety after smaller meals, which can be particularly effective for patients meeting the BMI for Wegovy criteria. The medication may also reduce food cravings by acting on brain appetite centres, supporting sustainable dietary changes. Unlike some weight management approaches, Wegovy's hormonal mechanism addresses underlying appetite regulation rather than simply restricting calories. This physiological approach explains why the medication is prescribed specifically for patients within defined BMI ranges where appetite dysregulation contributes to weight management challenges.
Streamlined BMI Assessment to Next Day Delivery
Our efficient process begins with a 3-minute online clinical assessment that evaluates your BMI for Wegovy eligibility alongside other health factors. Qualified prescribers review your submission within 3 working days (or 24 hours with express service), confirming both BMI criteria and overall suitability for treatment. Once approved, your Wegovy prescription enters our next day delivery system, packaged in temperature-controlled containers to maintain the 2-8°C storage requirements. Tracked delivery with signature confirmation ensures secure receipt, while our customer support team remains available throughout the process. This seamless journey from BMI verification to doorstep delivery typically completes within 4-5 working days of initial application.
Storage and Practical Guidance for BMI-Qualified Patients
Once your BMI for Wegovy assessment is complete and medication delivered, proper storage becomes essential for treatment success. Store unopened pens in the refrigerator at 2-8°C, though Wegovy can remain at room temperature below 30°C for up to 6 weeks once removed from cold storage - longer than some alternative medications. The FlexTouch pen system requires weekly injections, with mandatory dose escalation from 0.25mg through to 2.4mg maintenance dose over 16 weeks. Each pen contains multiple doses, and the injection process becomes routine for most patients within the first month. Always rotate injection sites between thigh, abdomen, or upper arm to maintain comfort and absorption consistency throughout your treatment journey.
BMI Verification and Express Delivery Service
Patients who calculate their BMI for Wegovy eligibility often prefer rapid prescription processing once they meet the criteria. Our express prescriber review service reduces standard 3-day assessment times to 24 hours, particularly valuable for those eager to begin treatment. This expedited service, combined with next day delivery, means eligible patients can receive their first Wegovy pen within 2-3 days of application completion.
The express pathway maintains all safety protocols while prioritising speed for time-conscious patients. BMI verification, medical history review, and contraindication screening occur within the accelerated timeframe, ensuring no compromise on clinical standards. Express processing particularly suits patients who have already discussed Wegovy with their GP and understand their eligibility, requiring only formal prescription authorisation through our regulated pharmacy services.
Complete Your BMI for Wegovy Assessment Today
Starting your weight management journey begins with confirming your BMI for Wegovy eligibility through our comprehensive online assessment. New customers benefit from the FIRST40 discount code applied at checkout, while returning patients use DOSE25 for continued savings. Our GPhC registered pharmacy #9012878 ensures full regulatory compliance throughout your treatment journey. Visit https://everydaymeds.co.uk/collections/wegovy to begin your assessment and experience the convenience of next day delivery for this prescription-only medicine. Join thousands of patients who have chosen EverydayMeds for reliable, fast Wegovy supply with complete clinical oversight and support.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
